Pharma and BioTech Daily
Pharma & Biotech Daily is a short, AI-generated, human-supervised briefing on what’s important in pharma and biotech.
Each weekday we condense key news on pipelines, deals, regulation and strategy into a quick audio update for people who build, run and invest in life sciences.
Produced by OWITH.ai, a boutique AI & data studio.
Sponsor the show: https://sponsor.owith.ai
Pharma and BioTech Daily
Latest Episodes
Beam Base Editing Sickle Cell Win, FDA Approves Pimjetmi | Pharma and Biotech Daily
Beam Therapeutics' base editing therapy risto-cel meets its primary endpoint in the pivotal BEACON sickle cell study, and the FDA approves Pimjetmi, pimicotinib, from Abbisko and Merck KGaA for tenosynovial giant cell tumor. Also: BIO's BioAdvance...
Vir Hepatitis Delta Phase 3 Win, argenx $1.15B Peptide Deal | Pharma and Biotech Daily
Vir Biotechnology reports a pivotal Phase 3 win in chronic hepatitis delta, and argenx agrees to buy Unnatural Products for up to 1.15 billion dollars to add oral macrocyclic peptides. Also: TG Therapeutics raises Briumvi guidance, Xenon's azetuka...
Lp(a)HORIZON Fails at AHA, FDA's Big November | Pharma and Biotech Daily
Full Lp(a)HORIZON results at AHA show Novartis' pelacarsen cut Lp(a) by 78 percent with no cardiovascular benefit, as the FDA heads into a crowded month of decisions on ivonescimab, deramiocel and povetacicept. Also: Mineralys' lorundrostat holds ...
Zealand Pharma & Generate Biomedicines' $1.2B AI Deal | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of exciting advancements and strategic shifts reshaping the landscape of drug develo...
GSK Invests $800M in Biologics Facility | Pharma and Biotech Daily
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into some of the most compelling stories shaping the industry. Let's begin with GSK's bold mo...